Trending...
- For Labor Day: Check out a poem about Labor and Manufacturing called "It used to be Made in America" - 207
- California prioritized fighting organized retail theft, those results are paying off with 36,000 arrests and $293 million in stolen goods recovered - 111
- California and the Australian state of Queensland ink new partnership to accelerate climate resilience, agricultural technology, and innovation - 108
Preliminary framework pairs NeoPathology's clinical network with Qscription's enterprise integration and U.S. operations capability.
MILWAUKEE - Californer -- Qscription Technologies Inc., a U.S. market-entry and clinical AI integration company, and NEOPATHOLOGY CORP., a biotechnology research and clinical diagnostic development company, today announced a Memorandum of Understanding (MOU).
Under the preliminary framework, the companies intend to explore joint commercialization and enterprise integration of an FDA 510(k)-cleared lung imaging AI diagnostic application in select U.S. healthcare markets. NEOPATHOLOGY brings its clinical network, diagnostic expertise, and clinical onboarding capability. Qscription contributes enterprise integration and U.S. operations support.
Regulator-cleared AI applications frequently stall between clearance and everyday clinical use, held up by IT integration, security review, and onboarding complexity. Under the proposed framework, NEOPATHOLOGY would lead clinical strategy, including securing programs, clinical onboarding, and region-specific medical compliance. Qscription would lead enterprise integration through its MedTech Operations capability, including integration with provider PACS and EHR environments, in material compliance with applicable HIPAA Security Rule and FDA requirements.
More on The Californer
"Clinical AI does not fail on science. It fails on integration and adoption," said Anurag Velekkatt Sunil Kumar, VP, MedTech Partnerships at Qscription Technologies. "NeoPathology's clinical network and commercialization strength, combined with our enterprise integration and U.S. operations capability, make a complete offering for the providers we serve."
"Our mission at NEOPATHOLOGY has always been centered on delivering highly accurate, rapidly reported diagnostics that meaningfully improve patient outcomes," said Paul Aiyetan, M.D., M.S., Ph.D., CEO and Director of Research, Development and Translation at NEOPATHOLOGY CORP. "Securing regulatory clearance is a critical milestone, but it is not the finish line. This MOU represents our proactive approach to ensuring that breakthrough tools can be safely, compliantly, and efficiently integrated into the hands of providers. By pairing our clinical development depth with Qscription's technical deployment framework, we are charting a reliable course from validation to clinical adoption."
The companies are now working toward a definitive commercial deployment agreement.
About NEOPATHOLOGY CORP.
NEOPATHOLOGY CORP. is a biotechnology research and clinical diagnostic development company advancing highly accurate, rapidly reported precision tissue diagnostics, anchored by its proprietary diagnostics platform and ONEPATHOLOGY(TM) learning solution. NEOPATHOLOGY is a Delaware corporation headquartered in Frederick, Maryland. https://neopathology.bio
More on The Californer
About Qscription Technologies
Qscription Technologies is the U.S. market-entry partner for global MedTech and clinical AI companies. Through its Decipher(TM) framework, Qscription provides regulatory presence, market access, enterprise integration, and U.S. operations support, turning FDA-cleared products into adopted products. Qscription is a Delaware corporation headquartered in Jackson, Wisconsin. https://qscription.tech
Read more: https://qscription.tech/blog/qscription-neopathology-mou
Media contacts
Qscription: Ajeesh Kumar, CTO, +1 715 449 8977
NEOPATHOLOGY: Paul Aiyetan, M.D., M.S., Ph.D., +1 (202) 810 3614
Under the preliminary framework, the companies intend to explore joint commercialization and enterprise integration of an FDA 510(k)-cleared lung imaging AI diagnostic application in select U.S. healthcare markets. NEOPATHOLOGY brings its clinical network, diagnostic expertise, and clinical onboarding capability. Qscription contributes enterprise integration and U.S. operations support.
Regulator-cleared AI applications frequently stall between clearance and everyday clinical use, held up by IT integration, security review, and onboarding complexity. Under the proposed framework, NEOPATHOLOGY would lead clinical strategy, including securing programs, clinical onboarding, and region-specific medical compliance. Qscription would lead enterprise integration through its MedTech Operations capability, including integration with provider PACS and EHR environments, in material compliance with applicable HIPAA Security Rule and FDA requirements.
More on The Californer
- Newport Harbor and Corona del Mar Set for Battle of the Bay Showdown at Davidson Field
- City of Long Beach Issues Heat Alert and Advises Residents to Take Precautions Against Heat
- Five International Travel Deals for Seniors Start at Just $995
- Interpreters Unlimited Recognized Among San Diego's 2026 Companies That Care
- IEI Launches Itten-E315, a 31.5-Inch Six-Color ePaper Display
"Clinical AI does not fail on science. It fails on integration and adoption," said Anurag Velekkatt Sunil Kumar, VP, MedTech Partnerships at Qscription Technologies. "NeoPathology's clinical network and commercialization strength, combined with our enterprise integration and U.S. operations capability, make a complete offering for the providers we serve."
"Our mission at NEOPATHOLOGY has always been centered on delivering highly accurate, rapidly reported diagnostics that meaningfully improve patient outcomes," said Paul Aiyetan, M.D., M.S., Ph.D., CEO and Director of Research, Development and Translation at NEOPATHOLOGY CORP. "Securing regulatory clearance is a critical milestone, but it is not the finish line. This MOU represents our proactive approach to ensuring that breakthrough tools can be safely, compliantly, and efficiently integrated into the hands of providers. By pairing our clinical development depth with Qscription's technical deployment framework, we are charting a reliable course from validation to clinical adoption."
The companies are now working toward a definitive commercial deployment agreement.
About NEOPATHOLOGY CORP.
NEOPATHOLOGY CORP. is a biotechnology research and clinical diagnostic development company advancing highly accurate, rapidly reported precision tissue diagnostics, anchored by its proprietary diagnostics platform and ONEPATHOLOGY(TM) learning solution. NEOPATHOLOGY is a Delaware corporation headquartered in Frederick, Maryland. https://neopathology.bio
More on The Californer
- Impact & Influence April 2026: Joel Rodriguez Tirado on Renewal,Growth & Uncomfortable Conversations
- Franchise Operators Are Standardizing Compliance Across Every Location in 2026
- Impact & Influence March 2026: Joel Rodriguez Tirado - Why You're Still Waiting & The Power of Start
- New Comparison Helps Senior Travelers Weigh Overseas Adventure Travel Against Road Scholar
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
About Qscription Technologies
Qscription Technologies is the U.S. market-entry partner for global MedTech and clinical AI companies. Through its Decipher(TM) framework, Qscription provides regulatory presence, market access, enterprise integration, and U.S. operations support, turning FDA-cleared products into adopted products. Qscription is a Delaware corporation headquartered in Jackson, Wisconsin. https://qscription.tech
Read more: https://qscription.tech/blog/qscription-neopathology-mou
Media contacts
Qscription: Ajeesh Kumar, CTO, +1 715 449 8977
NEOPATHOLOGY: Paul Aiyetan, M.D., M.S., Ph.D., +1 (202) 810 3614
Source: Qscription Technologies Inc
0 Comments
Latest on The Californer
- Skin Health Expert and Nurse Practitioner Blossom Inuenwi Launches 'The Glow Brief' Podcast
- AristoPup Grooming Launches "Fresh Start Grooming Days" to Help Palm Springs Animal Shelter Dogs
- New Edition of Bestselling Book Reveals How Consciousness Shapes Your Genes
- P&C Insurers -- Meet Me at ITC Vegas
- Happy Labor Day! California is the #1 for state for workers, #1 economy in the nation
- California: Governor Newsom proclaims Labor Day
- John Pape Releases Christian Single "The Road," Inspired by the Romans Road
- Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year
- TitleChain Foundation Issues Global Call to Build Public-Commons for Human-Controlled AI
- Lake Norman Philharmonic - Free Community Concert
- Los Angeles Massage Therapist Jesse Anoraj Places in Top Rankings at 2026 American Massage Championships
- City of Long Beach Issues Rain Advisory Due to Recent Showers
- Good Night, Oscar at North Coast Repertory Theatre
- Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range
- 99Websites Launches \$99 Done-for-You Website Service for Busy Professionals and Small Businesses
- Yalil Guerra's "Clave" to Receive World Premiere in New Symphonic Version at The Soraya
- solar bus stop led lighting for NCTD at 18 locations
- At 70, LA Woman Launches New E-Commerce Store One Year After Nerve Damage Left Her Unable to
- AI Visibility Campaign by 1stpage Reaches 800+ Citations Across Major AI Platforms in Four Months
- Apex Lane Logistics Surpasses 100-Truck Network as Southern California Freight Capacity Expands